Pinch
Well-Known Member
Medical Marijuana: National Multiple Sclerosis Society to Fund Study
6/23/06 Medical Marijuana: National Multiple Sclerosis Society to Fund Study
In what could be the first sign of a course reversal by the National Multiple Sclerosis Society, which has scoffed at medical marijuana in the past, the group announced this week that it will fund a study on the effect of marijuana on spasticity in MS patients. While the Society acknowledges that up to 15% of MS patients use medical marijuana, funding the new study is the first time the group has indicated it is hearing what those patients are saying.
The society currently rejects the use of marijuana to relieve MS symptoms. As it notes on its web site, "Based on the studies to date, it is the opinion of the National Multiple Sclerosis Society's Medical Advisory Board that there are currently insufficient data to recommend marijuana or its derivatives as a treatment for MS. Long-term use of marijuana may be associated with significant serious side effects. In addition, other well-tested, FDA-approved drugs are available, such as baclofen and tizanidine, to reduce spasticity in MS."
The Society said it was moved by inconclusive earlier studies on the effect of marijuana on MS spasticity to fund a one using a new measure. The study is not a new one; the group is taking over funding for ongoing research at the University of California Center for Medicinal Cannabis Research, which lost funding when the investigation was only partially completed.
The study, by Dr. Mark Agius and fellow researchers at the University of California-Davis School of Medicine, is scheduled for completion in March 2008.
6/23/06 Medical Marijuana: National Multiple Sclerosis Society to Fund Study
In what could be the first sign of a course reversal by the National Multiple Sclerosis Society, which has scoffed at medical marijuana in the past, the group announced this week that it will fund a study on the effect of marijuana on spasticity in MS patients. While the Society acknowledges that up to 15% of MS patients use medical marijuana, funding the new study is the first time the group has indicated it is hearing what those patients are saying.
The society currently rejects the use of marijuana to relieve MS symptoms. As it notes on its web site, "Based on the studies to date, it is the opinion of the National Multiple Sclerosis Society's Medical Advisory Board that there are currently insufficient data to recommend marijuana or its derivatives as a treatment for MS. Long-term use of marijuana may be associated with significant serious side effects. In addition, other well-tested, FDA-approved drugs are available, such as baclofen and tizanidine, to reduce spasticity in MS."
The Society said it was moved by inconclusive earlier studies on the effect of marijuana on MS spasticity to fund a one using a new measure. The study is not a new one; the group is taking over funding for ongoing research at the University of California Center for Medicinal Cannabis Research, which lost funding when the investigation was only partially completed.
The study, by Dr. Mark Agius and fellow researchers at the University of California-Davis School of Medicine, is scheduled for completion in March 2008.
